online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 4 of 9
Up
ECPB 2019, 88(4): 29–37
https://doi.org/10.25040/ecpb2019.04.029
Research articles

BIGUANIDES AND IMMUNE CHANGES IN PATIENTS WITH SYSTEMIC CONNECTIVE TISSUE DISEASES WITH A METABOLIC SYNDROME

I.G. GAIDUCHOK2, YU.V. FEDOROV1, KH.O. LISHCHUK-YAKIMOVICH1, R.M. PUKALYAK1, L.A. MOGYLNYTSKA3
Abstract

Increasing the number of immune-related complications of systemic connective tissue diseases requires continuous improvement of methods for their diagnosis and treatment. Despite the fact that significant advances have been made today in the study of systemic connective tissue diseases, the question of the use of maintenance therapy in patients, which may help to prevent their occurrence, remains relevant. Recent studies indicate that the use of biguanides (metformin), which have anti-inflammatory effects, is promising. Assessment of the status of the immune system patients with systemic connective tissue diseases, which received in the complex scheme of treatment of biguanides (metformin), determined the purpose of our work. 38 patients with systemic connective tissue diseases, aged 36–58 years, were examined. To confirm the main diagnosis (systemic connective tissue diseases), patients underwent clinical, general laboratory, immunological and instrumental studies, based on the results of which, according to international diagnostic criteria using international protocols, the following systemic connective tissue diseases were diagnosed: rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis. All patients who participated in the study were informed, in writing, that the studies were in accordance with the established standards of the Declaration of Helsinki adopted in 1964 and revised by the 59th General Assembly of the WMA (Seoul, October 2008). Investigated the total complementary activity of blood serum, the level of circulating immune complexes, the phagocytic activity of neutrophils and monocytes (absorptive capacity: spontaneous and stimulated; the ability to process: spontaneous, physiological, chemically strong and weak), population and subpopulation composition of lymphocytes before and after treatment. Statistical processing of the results of the study was carried out using generally accepted methods of variation statistics. Patients with systemic connective tissue disease receiving metformin in combination with baseline therapy showed normalization of total complementary activity of blood serum (p<0.05), stabilization of phagocytosis, as indicated increase in the spontaneous exciting ability of neutrophils by 1.1-fold (p<0.05) and strongly stimulated oxidative activity of monocytes by 1.1-fold (p<0.05), increase in induced absorption capacity of monocytes to the level of norm (p<0.05). The number of regulatory CD4+/25+ lymphocytes increased by 1.2-fold (p <0.05) and there was a tendency to normalize the number of activated T lymphocytes (CD3+/ HLA-DR+) (p<0.05). Patients with systemic connective tissue diseases, who received only basic therapy, showed a decrease in the number of T-helper cells (CD3+/4+) by 1.3-fold (p<0.05), of activated B lymphocytes (CD25+) by 2.2-fold (p<0.05) and T lymphocytes (CD3+/ HLA-DR+) by 2.0-fold (p<0.05). The peculiarities of the effect of metformin on indicators of the immune system of patients with systemic connective tissue diseases receiving long-term basic therapy give reason to view this drug as a promising prophylactic immunoregulatory factor in the development of immune-dependent disorders.

Received: 22.11.2019

Keywords: systemic connective tissue diseases, immune system, metformin

Full text: PDF (Ukr) 449K

References
  1. 1. Ambrosova TM. Efficiency of the use of metformin in type 2 diabetes: cardiovascular, protective and metabolic effects. Experiment. clin. med. 2013;(3):35-40.
  2. 2. Radchenko AN. The use of metformin in patients with diabetes mellitus: a view of a cardiologist. Arterial hypertension. 2011;(3):50-63).
  3. 3. Urbanovich AM Influence of metformin treatment on the content of some adipose tissue hormones and mediators of generalized nonspecific inflammation in patients with newly diagnosed type 2 diabetes. Intern Еndocrinol J. 2015;4(68):34-7).
  4. 4. Gross JL, Kramer CK, Leitão CB et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011;154(10):672-9. doi.org/10.7326/0003-4819-154-10-201105170-00007
  5. 5. Anabtawi A, Miles JM. Metformin: nonglycemic effects and potential novel indications. Endocr Pract. 2016;22(8):999-7. doi.org/10.4158/EP151145.RA
  6. 6. Cho K, Chung JY, Cho SK et al. Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway. Sci Rep. 2015;(5):8145. doi.org/10.1038/srep08145
  7. 7. Karavia EA, Hatziri A, Kalogeropoulou C et al. Deficiency in apolipoprotein A-I ablates the pharmacological effects of metforminon plasma glucose homeostasis and hepatic lipid deposition. Eur J Pharmacol. 2015;766:76-85. doi.org/10.1016/j.ejphar.2015.09.040
  8. 8. Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab. 2012;25(1-2):41-9. doi.org/10.1515/jpem-2011-0469
  9. 9. Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol. 2014;30(5):367-71. doi.org/10.3109/09513590.2014.887063
  10. 10. Markowicz-Piasecka M, Huttunen KM, Mateusiak L et al. Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics. Curr Pharm Des. 2017;23(17):2532-50. doi.org/10.2174/1381612822666161201152941
  11. 11. Krysiak R, Okopien B. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. Metabolism. 2013;62(1):39-43. doi.org/10.1016/j.metabol.2012.06.009
  12. 12. Chen H, Li J, Yang O et al. Effect of metformin on insulin-resistant endothelial cell function. Oncol Lett. 2015;9(3):1149-53.doi.org/10.3892/ol.2015.2883
  13. 13. Kinaan M, Ding H, Triggle CR. Metformin: an old drug for the treatment of diabetes but a new drug for the protection of the endothelium. Med Princ Pract. 2015;24(5):401-15. doi.org/10.1159/000381643
  14. 14. Jager J, Kooy A, Schalkwijk C et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014;275(1):59-70. doi.org/10.1111/joim.12128
  15. 15. Hamidi Shishavan M, Henning RH, van Buiten A et al. Metformin improves endothelial function and reduces blood pressure in diabetic spontaneously hypertensive rats independent from glycemia control: comparison to vildagliptin. Sci Rep. 2017;7(1):10975. doi.org/10.1038/s41598-017-11430-7
  16. 16. Cameron AR, Morrison VL, Levin D et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016;119(5):652-65. doi.org/10.1161/CIRCRESAHA.116.308445
  17. 17. Ismaiel AA, Espinosa-Oliva AM, Santiago M et al. Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system. Toxicol Appl Pharmacol. 2016;298:19-30. doi.org/10.1016/j.taap.2016.03.004
  18. 18. Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-5. doi.org/10.2174/1871530315666150316124019
  19. 19. Tomczyk R, Ociepka A, Kiałka M et al. Metformin and changes in blood pressure and heart rate in lean patients with polycystic ovary syndrome (PCOS). Przegl Lek. 2015;72(6):302-5.
  20. 20. Chopyak VV, Potemkina GO, Sinenkа MJ. et al. Systemic connective tissue diseases: experience. Ukr Rheumatol J. 2009;2(36):15-21.
  21. 21. Kuntal C, Ong VH., Denton CP. Secondary vasculitis in autoimmune connective tissue diseases. Curr Opin Rheumatol. 2016;28(1):60-5. doi.org/10.1097/BOR.0000000000000241
  22. 22. Sharma A, Dhooria A, Aggarwal A et al. Connective tissue disorder-associated vasculitis. Curr Rheumatol Rep. 2016;18(6):31. doi.org/10.1007/s11926-016-0584-x
  23. 23. Takakubo Y, Konttinen YT. Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol. 2012;2012:941346. doi.org/10.1155/2012/941346
  24. 24. Cozzani E, Gasparini G, Papini M et al. Vasculitis associated with connective tissue diseases. G Ital Dermatol Venereol. 2015;150(2):221-32.
  25. 25. Drannik GN. Clinical immunology and allergology. Kiev: Polygraphplus; 2010. 552 р.
  26. 26. Chop'yak VV. Systemic vasculitis. Lviv: LNMU named Danylo Halytsky; 2014. 320 p.
  27. 27. Chopyak VV, Boyko YY, Sinenkа MJ. A protocol approach to the delivery of medical care to patients with autoimmune rheumatic diseases: guidelines. Lviv; 2007. 47 p.
  28. 28. Osipov SG, Eremeev VV, Rudnev VI. Methods for the determination of immune complexes. Lab.work. 1983;(11):3-7.
  29. 29. Kolesnik NV, Omelyanchik LO. Methods of laboratory immunology. Zaporizhzhia: ZNU; 2010. 116 p.
  30. 30. Sokolenko VL, Sokolenko SV. Applied immunology. 2nd ed. Cherkasy: LEMAR-PROM; 2015. 66 p.
  31. 31. Glanz S. Biomedical statistics: trans. from еnglish. Moscow: Practice; 1998. 459 p.
  32. 32. Rebrovа OY. Statistical analysis of medical data. Application of STATISTICA application package. Moscow: Mediasphere; 2002. 312 р.
  33. 33. Rudneva E. Gelsinki Declaration of Ethical Principles: 2008 version. Ukr Med Chronicle. 2009;1(69):107-12.


Програмування - Roman.im